We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Compare Visual Outcomes Using a New Diagnostic Device

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04037631
Recruitment Status : Terminated (recruitment)
First Posted : July 30, 2019
Last Update Posted : January 28, 2021
Information provided by (Responsible Party):
Carl Zeiss Meditec AG

Brief Summary:
Evaluation of preoperative corrected distance visual acuity (CDVA) obtained with VirtIOL device compared to postoperative CDVA.

Condition or disease Intervention/treatment
Presbyopia Diagnostic Test: Diagnostic device

Layout table for study information
Study Type : Observational
Actual Enrollment : 24 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Prospective Clinical Study to Compare Visual Performance Obtained With a New Diagnostic Device
Actual Study Start Date : July 20, 2017
Actual Primary Completion Date : May 1, 2020
Actual Study Completion Date : May 1, 2020

Group/Cohort Intervention/treatment
Patients without clinically significant age-related cataract Diagnostic Test: Diagnostic device
Diagnostic test

Primary Outcome Measures :
  1. Corrected distance visual acuity (CDVA) [ Time Frame: 3 months after surgery ]
    Evaluation of CDVA obtained with diagnostic device

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients without clinically significant age-related cataract

Inclusion Criteria:

  • Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent
  • Patients of any gender, aged 18 years to open age
  • Assured follow-up examinations
  • Healthy eyes without clinically significant age-related cataract

    -Exclusion Criteria:

  • Patients unable to meet the limitations of the protocol or likely of non-cooperation during the trial
  • Patients whose freedom is impaired by administrative or legal order
  • Concurrent participation in another drug or device investigation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04037631

Layout table for location information
Internationale Innovative Ophthalmologie
Düsseldorf, Germany, 40549
Sponsors and Collaborators
Carl Zeiss Meditec AG
Layout table for additonal information
Responsible Party: Carl Zeiss Meditec AG
ClinicalTrials.gov Identifier: NCT04037631    
Other Study ID Numbers: AT-LISA-tri 839MP BER-401-17
First Posted: July 30, 2019    Key Record Dates
Last Update Posted: January 28, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Refractive Errors
Eye Diseases